-0.001 (-16.667%)
ASX:Live
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Valuation
Value
Consensus
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Description
AdAlta Ltd. operates as a biotechnology company, discovers, develops, and commercializes protein based therapeutics. The company was founded in 2007 and is headquartered in Bundoora, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.03
Trade Value (12mth)
AU$2,104.00
1 week
0%
1 month
-14.29%
YTD
-66.67%
1 year
-78.57%
All time high
0.38
EPS 3 yr Growth
-54.20%
EBITDA Margin
N/A
Operating Cashflow
-$5m
Free Cash Flow Return
-261.00%
ROIC
-267.00%
Interest Coverage
-60.90
Quick Ratio
2.40
Shares on Issue (Fully Dilluted)
610m
HALO Sector
Healthcare
Next Company Report Date
22-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
| Date | Announcements |
|---|---|
|
01 May 25 |
Quarterly Appendix 4C and Activities Report
×
Quarterly Appendix 4C and Activities Report |
|
30 April 25 |
Trading Halt
×
Trading Halt |
|
14 April 25 |
Notification of cessation of securities - 1AD
×
Notification of cessation of securities - 1AD |
|
14 April 25 |
Notification regarding unquoted securities - 1AD
×
Notification regarding unquoted securities - 1AD |
|
26 March 25 |
ASX Emerging Gems presentation
×
ASX Emerging Gems presentation |
|
20 March 25 |
SYNBV invest up to $2m in East to West subsidiary
×
SYNBV invest up to $2m in East to West subsidiary |
|
17 March 25 |
Application for quotation of securities - 1AD
×
Application for quotation of securities - 1AD |
|
17 March 25 |
Cleansing Notice
×
Cleansing Notice |
|
13 March 25 |
Investor presentation - Stocks on Track
×
Investor presentation - Stocks on Track |
|
05 March 25 |
R&D Tax Incentive advance received
×
R&D Tax Incentive advance received |
|
04 March 25 |
Company presentation - East-West Biopharma Summit
×
Company presentation - East-West Biopharma Summit |
|
21 February 25 |
Application for quotation of securities - 1AD
×
Application for quotation of securities - 1AD |
|
21 February 25 |
Cleansing Notice
×
Cleansing Notice |
|
20 February 25 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
|
11 February 25 |
Webinar presentation - East to West cell therapy strategy
×
Webinar presentation - East to West cell therapy strategy |
|
07 February 25 |
Investor Presentation
×
Investor Presentation |
|
07 February 25 |
Application for quotation of securities - 1AD
×
Application for quotation of securities - 1AD |
|
07 February 25 |
Cleansing Notice
×
Cleansing Notice |
|
06 February 25 |
East to West cell therapy strategy update
×
East to West cell therapy strategy update |
|
06 February 25 |
Investor webinar: East to West cell therapy strategy
×
Investor webinar: East to West cell therapy strategy |
|
04 February 25 |
AdAlta presenting at 3rd ANZ Biologics Festival
×
AdAlta presenting at 3rd ANZ Biologics Festival |
|
31 January 25 |
Quarterly Appendix 4C and Activities Report
×
Quarterly Appendix 4C and Activities Report |
|
13 January 25 |
Notification regarding unquoted securities - 1AD
×
Notification regarding unquoted securities - 1AD |
|
10 January 25 |
Investor Presentation
×
Investor Presentation |
|
05 December 24 |
Notification regarding unquoted securities - 1AD
×
Notification regarding unquoted securities - 1AD |
Load More
Load Less
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
.svg)
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.
